Usefulness of estimated average glucose (eAG) in glycemic control and cardiovascular risk reduction.

OBJECTIVE

One of the 8 regional health authority (RHA) zones in New Brunswick, Canada has implemented eAG since 2010. We sought to evaluate the clinical outcomes of glycemic control and cardiovascular risk levels before and after the eAG implementation in this zone; and to compare the overall outcomes of this zone with other 7 zones of the province.

METHODS

Data (838,407 HbA1c values and 612,314 LDL-c values) was extracted from all adult diabetic patients in the provincial Diabetes Registry from 2008 to 2014. The Kruskal-Wallis statistic was conducted to compare the medians and inter quartile ranges of HbA1c and LDL-c from different zones. The proportion of patients achieving therapeutic targets, the distribution of HbA1c and LDL-c values pre/post the eAG implementation in RHA Zone 1.1 were assessed by Chi-square analysis.

RESULTS

The proportion of patients achieving targets in Zone 1.1 were at an intermediate level among all 8 zones and the trends of Zone 1.1 were no different than other zones. There were statistically significant differences for Zone 1.1 in the distribution of HbA1c (Z = -12.5190, P < 0.001) and LDL-c (Z = 16.4410, P < 0.001) before and after the eAG reported. The proportion of patients with HbA1c < 53 mmol/mol (7.0%) of the RHA Zone 1.1 was significantly lower after eAG reported (49.85% vs. 47.24%, P < 0.001); while the proportion of patients with LDL-c < 2.6 mmol/L showed statistically significant increase (68.56% vs. 71.90%, P < 0.001).

CONCLUSION

The utilization of eAG has demonstrated no significant impact on glycemic control and cardiovascular risk reduction.